Nina Kjellson has served on Ocera’s board of directors since June 2011.Ms. Kjellson is a managing director at InterWest Partners, a venture capital firm, where she has been employed since 2002.From June 2000 to June 2002, she served as an investment manager at Bay City Capital, a life sciences merchant bank, and from October 1999 to June 2000, as a research associate at Oracle Partners, a healthcare-focused hedge fund.
From August 1997 to September 1999, Ms. Kjellson conducted health policy and survey research with the Kaiser Family Foundation, a private foundation focusing on healthcare issues.She holds a B.A. in Human Biology from Stanford University. Ms. Kjellson currently serves on the board of directors of Trius Therapeutics, Inc., a publicly held company.
BA, Human biology1997
|May 10, 2016||Xconomy - Across The Board: Ideas To Narrow Biotech’s Gender Gap|
|Mar 11, 2016||Startup Daily - Facebook acquires Masquerade; WeWork raises $430 million at $16 billion valuation; PlantMiner raises $3.5 million|
|Mar 8, 2016||PE HUB - Abingworth, Canaan lead $43 mln Series B for Tizona Therapeutics|
|Mar 8, 2016||Business Wire - Tizona Therapeutics, Inc., Completes $43 Million Series B Financing|
|Nov 19, 2015||Xconomy - Agenda Posted: Xconomy’s Bay Area Life Science Disruptors On Dec. 10|
|Feb 9, 2015||Venture Beat - Network with the top CEOs & VCs in digital health tech at Vator Splash Health (20% discount for VB readers)|
|Jun 30, 2014||FinSMEs - Cidara Therapeutics Completes $32M Series A Financing|
|Jun 25, 2014||Xconomy - San Diego Biotech Raises Over $30M to Fight Deadly Fungal Infections|